Mallinckrodt (MNK) Valuation Range, Estimates Cut at Wells Fargo on Methyphenidate ER Issue

October 18, 2016 7:59 AM EDT
Get Alerts MNK Hot Sheet
Price: $50.64 --0%

Rating Summary:
    17 Buy, 4 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 0 | Down: 0 | New: 0
Trade MNK Now!
Join SI Premium – FREE

Find out which companies are about to raise their dividend well before the news hits the Street with's Dividend Insider Elite. Sign-up for a FREE trial here.

Wells Fargo analyst David Maris lowered his valuation range on Mallinckrodt plc (NYSE: MNK) from $88-$89 to $83-$84 after the the FDA announced a proposal to withdraw approval of an ANDA for methylphenidate hydrochloride (HCl) extended-release (ER) tablets.

The firm lowered Q4 estimate by $0.04 from $1.90 to $1.86 based on the assumption MNK's generic methylphenidate ER is pulled from the market this quarter. In addition, they reduced 2017 estimate by $0.50 from $8.25 to $7.75.

The firm maintained an Outperform rating.

For an analyst ratings summary and ratings history on Mallinckrodt plc click here. For more ratings news on Mallinckrodt plc click here.

Shares of Mallinckrodt plc closed at $64.96 yesterday.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, Analyst EPS Change, Analyst PT Change

Related Entities

Wells Fargo, David Maris

Add Your Comment